HC Wainwright Issues Pessimistic Outlook for HOWL Earnings

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Equities researchers at HC Wainwright lowered their Q1 2025 EPS estimates for Werewolf Therapeutics in a report issued on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.43) for the quarter, down from their prior estimate of ($0.38). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($1.56) EPS, FY2028 earnings at ($1.07) EPS and FY2029 earnings at ($0.64) EPS.

HOWL has been the topic of a number of other research reports. Wedbush reiterated an “outperform” rating and issued a $8.00 price target on shares of Werewolf Therapeutics in a report on Wednesday, March 12th. JMP Securities decreased their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a report on Tuesday, January 14th.

Werewolf Therapeutics Stock Down 0.8 %

Shares of HOWL opened at $1.20 on Monday. The firm has a market cap of $53.79 million, a PE ratio of -0.78 and a beta of 0.37. The company’s fifty day moving average is $1.35 and its two-hundred day moving average is $1.80. Werewolf Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $6.89. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of Werewolf Therapeutics by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock valued at $1,454,000 after acquiring an additional 40,692 shares in the last quarter. Barclays PLC lifted its holdings in shares of Werewolf Therapeutics by 130.1% during the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock valued at $116,000 after acquiring an additional 30,990 shares in the last quarter. State Street Corp increased its stake in Werewolf Therapeutics by 12.4% during the 3rd quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares during the period. Walleye Capital LLC increased its stake in Werewolf Therapeutics by 10.7% during the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares during the period. Finally, Levin Capital Strategies L.P. purchased a new stake in Werewolf Therapeutics during the 4th quarter worth $74,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.